CENTESSA PHARMACEUTICALS PLC

Historical 13F Holders

Symbol
CNTA
CUSIP
152309100
All holders as of
Q1 2026
Type
Equity
Class
SPONSORED ADS
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 152309100 since 12/18/2024, newest first.

Filer % of Class Filed
Index Ventures Life VI (Jersey) L.P. 13G/A Amendment 1
0% 8/14/2026
Event 6/30/2026
Pentwater Capital Management LP 13G/A Amendment 1
0% 8/14/2026
Event 6/30/2026
Adage Capital Management, L.P. 13G/A Amendment 4
0% 8/12/2026
Event 6/30/2026
Medicxi Growth I LP 13G/A Amendment 2
0% 8/4/2026
Event 6/30/2026
FMR LLC 13G/A Amendment 4
0% 7/8/2026
Event 6/30/2026
Farallon Capital Management, L.L.C. 13D/A Amendment 1
0% 6/26/2026
Event 6/24/2026
Farallon Capital Management, L.L.C. 13D
6.1% 6/24/2026
Event 6/16/2026
Pentwater Capital Management LP 13G
5.3% 5/15/2026
Event 3/31/2026
Avoro Capital Advisors LLC 13G/A Amendment 2
7.4% 5/15/2026
Event 3/31/2026
Adage Capital Management, L.P. 13G/A Amendment 3
5.8% 5/13/2026
Event 3/31/2026
FMR LLC 13G/A Amendment 3
7.5% 5/6/2026
Event 3/31/2026
Avoro Capital Advisors LLC 13G/A Amendment 1
10.0% 2/17/2026
Event 12/31/2025
FMR LLC 13G/A Amendment 2
12.2% 2/6/2026
Event 1/30/2026
FMR LLC 13G/A Amendment 1
9.9% 2/5/2026
Event 12/31/2025
General Atlantic Cooperatief U.A. 13D/A Amendment 2
5.0% 11/28/2025
Event 11/25/2025
General Atlantic Cooperatief U.A. 13D/A Amendment 1
6.6% 11/17/2025
Event 11/17/2025
Avoro Capital Advisors LLC 13G
8.1% 11/14/2025
Event 9/30/2025
Adage Capital Management, L.P. 13G/A Amendment 2
7.5% 11/13/2025
Event 9/30/2025
FMR LLC 13G
7.0% 11/5/2025
Event 9/30/2025
Adage Capital Management, L.P. 13G/A Amendment 1
6.3% 8/12/2025
Event 6/30/2025
Adage Capital Management, L.P. 13G
5.2% 5/12/2025
Event 3/31/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q1 177 149 M $5.90 B
2025 Q4 160 144 M $3.60 B
2025 Q3 143 129 M $3.12 B
2025 Q2 129 124 M $1.62 B
2025 Q1 144 125 M $1.80 B
2024 Q4 119 124 M $2.08 B
2024 Q3 109 109 M $1.74 B
2024 Q2 87 89.0 M $804 M
2024 Q1 76 78.7 M $889 M
2023 Q4 65 72.5 M $577 M
2023 Q3 53 72.6 M $470 M
2023 Q2 48 70.3 M $435 M
2023 Q1 45 66.9 M $258 M
2022 Q4 46 63.9 M $233 M
2022 Q3 46 74.8 M $300 M
2022 Q2 42 71.8 M $350 M
2022 Q1 46 74.6 M $670 M
2021 Q4 49 71.9 M $808 M
2021 Q3 41 56.9 M $947 M
2021 Q2 51 47.4 M $1.05 B